Transgenic mice overexpressing human G972R IRS-1 show impaired insulin action and insulin secretion

Journal of Cellular and Molecular Medicine

Volumn 12, Issue 5B, 2008, Pages 2096-2106

  Hribal, Marta L ^a,b   Tornei, F ^b   Pujol, A ^c   Menghini, R ^b   Barcaroli, D ^b   Lauro, D ^b   Amoruso, R ^b   Lauro, R ^b   Bosch, F ^c   Sesti, G ^a   Federici, M ^b  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Glucose intolerance; Insulin resistance; Insulin signalling; Mouse model

Indexed keywords

ADIPOCYTOKINE; ANTIDIABETIC AGENT; ARGININE; GLUCOSE; INSULIN; INSULIN RECEPTOR SUBSTRATE; IRS1 PROTEIN, HUMAN;

ADIPOSE TISSUE; AMINO ACID SUBSTITUTION; ANIMAL; ARTICLE; DRUG EFFECT; GENETICS; GLUCOSE TOLERANCE TEST; GLYCOGEN LIVER LEVEL; HUMAN; INSULIN RESISTANCE; LIVER; MALE; METABOLISM; MOUSE; SECRETION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TRANSGENIC MOUSE;

ADIPOKINES; ADIPOSE TISSUE; AMINO ACID SUBSTITUTION; ANIMALS; ARGININE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN RESISTANCE; LIVER; LIVER GLYCOGEN; MALE; MICE; MICE, TRANSGENIC; MUSCLE, SKELETAL; SIGNAL TRANSDUCTION;

MUS; MUS MUSCULUS;

EID: 55149110908     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2008.00246.x     Document Type: Article

References (28)

1. Taniguchi CM, Emmanuelli B, Kahn CR. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol. 2006 7 : 85 96.
2. Sesti G, Federici M, Hribal ML, Lauro D, Sbraccia P, Lauro R. Defects of the insulin receptor (IRS) system in human metabolic disorders. Faseb J. 2001 15 : 2099 111.
3. Almind K, Bjorbaek C, Vestergaard H, Hanset T, Echwald S, Pedersen O. Aminoacid polymorphism of insulin receptor substrate-1 in non-insulin-dependent diabetes mellitus. Lancet. 1993 342 : 828 32.
4. Imai Y, Fusco A, Suzuki Y, Lesniak MA, D'Alfonso R, Sesti G, Bertoli A, Lauro R, Accili D, Taylor SI. Variant sequences of IRS-1 in patients with noninsulin-depend-ent diabetes mellitus. J Clln Endocrlnol Metab. 1994 79 : 1655 8.
5. Almind K, Inoue G, Pedersen O, Kahn CR. A common amino acid polymorphism in insulin receptor substrate-1 causes impaired insulin signaling. Evidence from transgene studies. J Clln Invest. 1996 97 : 2569 75.
6. Hribal ML, Federici M, Porzio O Lauro D, Borboni P, Accili D, Lauro R, Sesti G. The Gly-> Arg amino acid polymorphism in insulin receptor substrate-1 affects glucose metabolism in skeletal muscle cells. J Clln Endocrlnol Metab. 2000 85 : 2004 13.
7. Porzio O, Federici M, Hribal ML Lauro D, Accili D, Lauro R, Borboni P, Sesti G. The Gly 972-> Arg amino acid polymorphism in IRS-1 impairs insulin secretion in pancreatic β cells. J Clln Invest 1999 104 : 357 64.
8. Federici M, Hribal ML, Ranalli M Marselli L, Porzio O, Lauro D, Borboni P, Lauro R, Marchetti P, Melino P, Sesti G. The common Arg972 polymorphism in insulin receptor substrate-1 causes apop-tosis of human pancreatic islets. FASEB J. 2001 15 : 22 4.
9. Federici M, Pandolfi A, De Filippis EA Pellegrini G, Menghini R, Lauro D, Cardellini M, Romano M, Sesti G, Lauro R, Consoli A. G972R IRS-1 variant impairs insulin regulation of endothelial nitric oxide synthase in cultured human endothelial cells. Circulation. 2004 109 : 399 405.
10. McGettrick AJ, Feeners EP, Kahn CR. Human Insulin Receptor Substrate-1 (IRS-1) Polymorphism G972R Causes IRS-1 to Associate with the Insulin Receptor and Inhibit Receptor Autophosphorylation. J BiolChem. 2005 280 : 6441 6.
11. Jellema A, Zeegers MP, Feskens EJ, Dagnelie PC, Mensink RP. Gly972Arg variant in the insulin receptor substrate-1 gene and association with Type 2 diabetes: a meta-analysis of 27 studies. Diabetologia. 2003 46 : 990 5.
12. van Dam RM, Hoebee B, Seidell JC, Schaap, MM, Blaak EE, Feskens EJ. The insulin receptor substrate-1 Gly972Arg polymorphism is not associated with Type 2 diabetes mellitus in two population-based studies. Diabetes Med. 2004 21 : 752 8.
13. Florez JC, Sjogren M, Burtt N, Orho-Melander M, Schayer S, Sun M, Almgren P, Lindblad U, Tuomi T, Gaudet D, Hudson TJ, Daly MJ, Ardlie KG, Hirschhorn JN, Altshuler D, Groop L. Association testing in 9,000 people fails to confirm the association of the insulin receptor substrate-1 G972R polymorphism with type 2 diabetes. Diabetes. 2004 53 : 3313 8.
14. Laukkanen O, Pihlajamaki J, Lindstrom J, Eriksson J, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Tuomilehto J, Uusitupa M, Laakso M. Common polymorphisms in the genes regulating the early insulin signalling pathway: effects on weight change and the conversion from impaired glucose tolerance to Type 2 diabetes. The Finnish Diabetes Prevention Study. Diabetologia. 2004 47 : 871 7.
15. Lyssenko V, Almgren P, Anevski D Orho-Melander M, Sjogren M, Saloranta C, Tuomi T, Groop L. Genetic prediction of future type 2 diabetes Plos Med 2005 2 : e345.
16. Riu E, Mas A, Ferre T, Pujol A, Gros L, Otaegui P, Montoliu L, Bosch F. Counteraction of Type 1 diabetic alterations by engineering skeletal muscle to produce insulin. Insights from transgenic mice. Diabetes. 2002 51 : 704 11.
17. Federici M, Hribal ML, Menghini R, Kanno H, Marchetti V, Porzio O, Sunnarborg SW, Rizza S, Serino M, Console V, Lauro D, Mauriello A, Smookler DS, Sbraccia P, Sesti G, Lee DC, Khokha R, Accili D, Lauro R. Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-α. J Clin Invest. 2005 115 : 3494 505.
18. Zisman, A. Peroni OD, Abel ED, Michael MD, Mauvais-Jarvis F, Lowell BB, Wojtaszewski JF, Hirshman MF, Virkamaki A, Goodyear LJ, Kahn CR, Kahn BB. Targeted disruption of the glucose transporter 4 selectively in muscle causes insulin resistance and glucose intolerance. Nat. Med. 2000 6 : 924 8.
19. Okamoto H, Hribal ML, Lin HV, Bennet WR, Ward A, Accili D. Role of the fork-head protein FoxOI in beta cell compensation to insulin resistance. J Clin Invest 2006 116 : 775 82.
20. Hansotia T, Maida A, Flock G, Yamada Y, Tsukiyama K, Seino Y, Drucker DJ. Extrapancreatic incretin receptors modulate glucose homeostasis, body weight, and energy expenditure. J Clin Invest 2007 117 : 143 52.
21. Kulkarni RN, Winnay JN, Daniels M, Briining JC, Flier SN, Hanahan D, Kahn CR. Altered function of insulin receptor substrate-1 deficient mouse islets and cultured β-cell lines. J Clin Invest. 1999 104 : R69 75.
22. Martin TL, Alquier T, Asakura K, Furukawa N, Preitner F, Kahn BB. Diet-induced obesity alters AMP kinase activity in hypothalamus and skeletal muscle. J BiolChem. 2006 281 : 18933 41.
23. Clausen JO, Hansen T, Bjobaerk C, Echwald SM, Urhammer SA, Rasmussen S, Andersen CB, Hansen L, Almind K, Whinter K, Haraltlsdottir J, Borch-Johnsen K, Pedersen O. Insulin resistance: interactions between obesity and a common variant of insulin receptor substrate-1. Lancet. 1995 346 : 397 402.
24. Baroni MG, Leonetti F, Sentinelli F, Romeo S, Filippi E, Fanelli M, Ribaldo MC, Zappaterreno A, Fallarono M, Di Mario U. The G972R variant of the insulin receptor substrate-1 (I RS-1) gene is associated with insulin resistance in "uncomplicated" obese subjects evaluated by hyper-insulinemic- euglycemic clamp. J Endocrinol Invest. 2004 27 : 754 9.
25. Hribal ML, Perego L, Cardellini M, Paganelli M, Andreozzi F, Pontiroli A, Folli F, Sesti G. Gene expression profiling in adipose tissue of G972 IRS-1 carriers. Diabetes. 2005 54, Suppl.1 : A270.
26. Sesti G, Marini MA, Cardellini M, Sciacqua A, Frontoni S, Andreozzi F, Irace C, Lauro D, Gnasso A, Federici M, Perticone, Lauro R. The Arg972 variant in insulin receptor substrate-1 is associated with an increasing risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care. 2004 27 : 1394 8.
27. Tschritter O, Preissl H, Hennige AM, Stumvoll M, Porubska K, Frost R, Marx H, Klosel B, Lutzenberger W, Birbaumer N, Haring HU, Fritsche A. The cerebrocor-tical response to hyperinsulinemia is reduced in overweight humans: a magne-toencephalographic study. Proc Natl Acad Sci USA. 2006 103 : 12103 8.
28. Woodcock J. The prospects for "personalized medicine" in drug development and drug therapy. Clin Pharmacol Ther 2007 81 : 164 9.